PharmaJet needle-free delivery enhances immune response and provides safety, efficacy, efficiency, and patient comfort for ...

Learn the essential steps for employees when responding to accidents in the workplace – that preserves the scene and ensures ...

According to UR President Sarah Manglesdorf, several of the people depicted in the posters appeared to have been targeted ...

The university said it was working to remove the posters but the process was extensive because of the strong adhesive used.

Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

The poster to be presented at ASH 2024 will provide a clinical ... or myelodysplastic syndrome (MDS)/AML. MP0533 showed an acceptable safety profile in the first 7 dose cohorts, with the majority of ...

Most RCC patients surveyed said telemedicine visits are comparable to in-person visits, but most oncology providers disagreed ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

The Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease, is ...